Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-02
2009-10-20
Davis, Zinna N (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S414000, C514S415000, C546S113000, C548S454000, C548S516000
Reexamination Certificate
active
07605168
ABSTRACT:
Compounds are described that are active on PDE4. Also described are crystal structures of PDE4B determined using X-ray crystallography, the use of PDE4B crystals and structural information for identifying molecular scaffolds, for developing ligands that bind to and modulate PDE4B, and for identifying improved ligands based on known ligands.
REFERENCES:
patent: 4150949 (1979-04-01), Smith
patent: 4568649 (1986-02-01), Bertoglio-Matte
patent: 4626513 (1986-12-01), Burton et al.
patent: 4861891 (1989-08-01), Saccomano et al.
patent: 5143854 (1992-09-01), Pirrung et al.
patent: 5426039 (1995-06-01), Wallace et al.
patent: 5434049 (1995-07-01), Okano et al.
patent: 5449614 (1995-09-01), Danos et al.
patent: 5474935 (1995-12-01), Chatterjee et al.
patent: 5556752 (1996-09-01), Lockhart et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5631236 (1997-05-01), Woo et al.
patent: 5632957 (1997-05-01), Heller et al.
patent: 5658775 (1997-08-01), Gilboa
patent: 5700637 (1997-12-01), Southern
patent: 5721118 (1998-02-01), Scheffler
patent: 5744305 (1998-04-01), Fodor et al.
patent: 5747276 (1998-05-01), Hoch et al.
patent: 5763198 (1998-06-01), Hirth et al.
patent: 5770456 (1998-06-01), Holmes
patent: 5800992 (1998-09-01), Fodor et al.
patent: 5807522 (1998-09-01), Brown et al.
patent: 5830645 (1998-11-01), Pinkel et al.
patent: 5840485 (1998-11-01), Lebl et al.
patent: 5856174 (1999-01-01), Lipshutz et al.
patent: 5877007 (1999-03-01), Housey
patent: 5922557 (1999-07-01), Pon
patent: 5959098 (1999-09-01), Goldberg et al.
patent: 5965452 (1999-10-01), Kovacs
patent: 6013440 (2000-01-01), Lipshutz et al.
patent: 6022963 (2000-02-01), McGall et al.
patent: 6025155 (2000-02-01), Hadlacsky et al.
patent: 6045996 (2000-04-01), Cronin et al.
patent: 6048695 (2000-04-01), Bradley et al.
patent: 6054270 (2000-04-01), Southern
patent: 6090912 (2000-07-01), Lebl et al.
patent: 6096718 (2000-08-01), Weitzman et al.
patent: 6107478 (2000-08-01), Pederson et al.
patent: 6110456 (2000-08-01), During
patent: 6110458 (2000-08-01), Freeman et al.
patent: 6113913 (2000-09-01), Brough et al.
patent: 6117681 (2000-09-01), Salmons et al.
patent: 6178384 (2001-01-01), Kolossvåry
patent: 6243980 (2001-06-01), Bronstein et al.
patent: 6258606 (2001-07-01), Kovacs
patent: 6261776 (2001-07-01), Pirrung et al.
patent: 6277489 (2001-08-01), Abbott et al.
patent: 6277628 (2001-08-01), Johann et al.
patent: 6288234 (2001-09-01), Griffin
patent: 6294330 (2001-09-01), Michnick et al.
patent: 6500610 (2002-12-01), Pamukcu et al.
patent: 6559168 (2003-05-01), Marfat et al.
patent: 2001/0008765 (2001-07-01), Shinoki et al.
patent: 2001/0012537 (2001-08-01), Anderson et al.
patent: 2001/0014448 (2001-08-01), Chappa et al.
patent: 2001/0014449 (2001-08-01), Nerenberg et al.
patent: 2001/0016322 (2001-08-01), Caren et al.
patent: 2001/0018642 (2001-08-01), Balaban et al.
patent: 2001/0019827 (2001-09-01), Dawson et al.
patent: 2002/0009764 (2002-01-01), Thompson et al.
patent: 2002/0165237 (2002-11-01), Fryburg et al.
patent: 2003/0064374 (2003-04-01), Ait Ikhlef et al.
patent: 2004/0106641 (2004-06-01), Hofgen et al.
patent: 0154734 (1985-09-01), None
patent: 0 667 345 (1995-08-01), None
patent: 1 166 785 (2002-01-01), None
patent: WO 96/17958 (1996-06-01), None
patent: WO 96/18738 (1996-06-01), None
patent: WO 97/46313 (1997-12-01), None
patent: WO 98/45268 (1998-10-01), None
patent: WO 99/09217 (1999-04-01), None
patent: WO 99/20625 (1999-04-01), None
patent: WO 99/21845 (1999-05-01), None
patent: WO 99/51773 (1999-10-01), None
patent: WO 01/02369 (2001-01-01), None
patent: WO 2005/016924 (2005-02-01), None
patent: WO 02/062290 (2006-08-01), None
Spina, D., Br J Pharmacol. 2008, 155(3):308-15.
Ghavami et al., Drugs R D. 2006, 7(2):63-71.
Smith et al., Blood 2005, 105(1):308-16.
Kim, DH and Lerner, A., Blood 1998, 92(7):2484-94.
Lee F-Y et al. “Synthesis of 1-benzyl-3-(5′-hydroxymethyl-2′-furyl) indazole Analogues as Novel Antiplatelet Agents” Journal of Med. Chem, Amer. Can Society, vol. 44, 3746-3749, 2001.
Ciattini, P.G. et al. “An efficient synthesis fo 3-substituted indoles by palladium-catalyzed coupling reaction of 3-tributylstannylindoles with organic triflates and halides” Tetrhedron Letters Vo. 35, No. 15, 1994 2405-2408.
PCT International Search Report Form PCT/ISA/210 dated Nov. 6, 2006.
Card et al., Structural basis for the activity of drugs that inhibit phosphodiesterases, 12:2233-2247, 2004.
Dym et al., Molecular docking of competitive phosphodiesterase inhibitors, Molecular Pharmacology, 61:20-25, 2002.
Haddad et al., Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (Interleukin-6 and tumor necrosis factor-α) Biosynthesis in alveolar epithelial cells, The Journal of Pharmacology and Experimental Therapeutics, 300:559-566, 2002.
Ho et al., Structure of the GAF domain, a ubiquitous signaling motif and a new class of cyclic GMP receptor, The EMBO Journal, 19(20):5288-5299, 2000.
Huai et al., Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity, Structure, 11:865-873, 2003.
Manning et al., Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B, British Journal of Pharmacology, 128:1393-1398, 1999.
Rascon et al., Cloning and characterization of a cAMP-specific phosphodiesterase (TbPDE2B) fromTrypanosoma brucei, PNAS, 99(7):4714-4719, 2002.
Sopory et al., Modeling and mutational analysis of the GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase, PDE5, FEBS Letters, 539:161-166, 2003.
Tejada et al., The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil, International Journal of Impotence Research, 13:282-290, 2001.
Turko et al., Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds, Mol Pharmacol, 56:124-130, 1999.
Abdelhamid, et. al., Reactions with Hydrazonoyl Halides. Part 21. Reinvestigation of the Reactions of Hydrazonoyl Bromides with 1,1-Dicyanothioacetanilide,J. Chem. Res., 184-185 (1999).
Alfthan, “Surface plasmon resonance biosensors as a tool in antibody engineering,”Biosensors&Bioelectronics. 13:653-63 (1998).
al-Obeidi, “Peptide and Petidomimetic Libraries”Mol Biotechnol9(3):205-23 (1998).
Amersdorfer P. Marks JD., “Phage Libraries for Generation of Anti-botulinum scFv Antibodies,”Methods in Molecular Biology, 145:219-40 (2001).
Bartlett et al., “Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules,” in Chemical and Biological Problems in Molecular Recognition, Roberts, S.M.; Ley, S.V.; Campbell, M.M. eds.;Royal Society of Chemistry: Cambridge, pp. I82-I96 (1989).
Bagshaw, C.R. and Harris, D.A., “Measurement of Ligand Binding to Proteins,”Spectrophotometry and Spectrofluorometry: A Practical Approach, Bashford, C.L. and Harris, D.A., eds.; pp. 91-114, IRL Press Ltd., Oxford, U.K., (1987).
Beavo, et al., “Multiple Cyclic Nucleotide Phosphodiesterases,”Mol. Pharmacol., 46:399-405 (1994).
Bell, J.E.,Spectroscopy In Biochemistry, vol. I, pp. 155-194, CRC Press, (1981).
Berthet, et al., “The Assay of Glucagon and Epinephrine with Use of Liver Homogenates,”J. Biol. Chem., 229:351-361 (1957).
Blundell et al., “Knowledge-based protein modeling and design.”Eur. J. Biochem., 172:513-520 (1988).
Böhm, H., “On the use of LUDI to search the Fine Chemicals Director for ligands of proteins of known three-dimensional structure,”J. Comp. Aided Molec. Design8: 623-632 (1994).
Bolger et al., “A Family of Human Phosphodiesterases Homologous to thedunceLearning and Memory Gene Product ofDrosophila melanogasterAre Potential Targets for Antidepressant Drugs,”Mol. Cell. Biol.13 (10), 6558-6571 (1993).
Bolger
Artis Dean R.
Bremer Ryan
Cho Hanna
Gillette Sam
Ibrahim Prabha N.
Davis Zinna N
Foley & Lardner LLP
Plexxikon Inc.
LandOfFree
PDE4B inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PDE4B inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PDE4B inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4077090